What evidence supports the use of glucagon-like peptide-1 (GLP-1) receptor agonists in treating severe psoriasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

GLP-1 Receptor Agonists for Severe Psoriasis

GLP-1 receptor agonists show promising efficacy for severe psoriasis, particularly in patients with obesity or type 2 diabetes, and should be considered as adjunctive therapy or as an alternative when conventional immunomodulatory therapies are contraindicated. 1, 2

Current Guideline Context

The most recent AAD-NPF guidelines 3 and GRAPPA recommendations 4 do not include GLP-1 agonists in their treatment algorithms. These guidelines strongly recommend biologics (TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors), JAK inhibitors, and PDE4 inhibitors for moderate to severe psoriasis. However, these guidelines predate the emerging evidence on GLP-1 agonists.

Evidence for GLP-1 Agonists in Severe Psoriasis

Clinical Efficacy

The strongest recent evidence comes from a 2026 cohort study demonstrating that 44.4% of patients with obesity and psoriasis achieved an Investigator's Global Assessment (IGA) score of 0/1 with GLP-1 therapy, compared to only 12.1% in controls (p<0.001) 1. This represents a clinically meaningful difference in achieving clear or almost clear skin.

Key efficacy findings across studies:

  • PASI reductions range from 40-80% with parallel quality-of-life improvements 2
  • A randomized controlled trial showed significant improvements in both PASI and DLQI scores after 12 weeks of liraglutide treatment 5
  • Greater weight loss correlates with more rapid psoriasis response (τ = -0.59; p<0.001) 1
  • Among patients already on biologics, adding GLP-1 therapy resulted in superior response rates (p=0.029) 1

Agent-Specific Considerations

Semaglutide and liraglutide demonstrate the most consistent evidence of benefit 6, 2. These agents have been associated with:

  • Reductions in inflammatory markers (C-reactive protein, IL-6, IL-17, IL-23, TNF-α) 5, 2
  • Decreased visceral adiposity and dermal γδ T-cell density 2
  • Improvements in cardiometabolic parameters beyond psoriasis control 6

Tirzepatide (dual GIP/GLP-1 agonist) and exenatide also show promise, though with less robust data 6.

Mechanisms of Action

GLP-1 agonists work through dual pathways:

  1. Systemic metabolic effects: Weight loss, improved glycemic control, reduced visceral adiposity
  2. Direct immunomodulation: Regulation of invariant natural killer T cells, AMPK activation in psoriatic plaques, suppression of IL-17/IL-23/TNF-α pathways 5, 7

This dual mechanism addresses both the inflammatory and metabolic components of psoriasis pathogenesis.

Clinical Algorithm for Use

Consider GLP-1 agonists in the following scenarios:

  1. Primary indication: Severe psoriasis with BMI ≥27 and/or type 2 diabetes
  2. Adjunctive therapy: Patients on biologics with suboptimal response who have metabolic comorbidities
  3. Alternative therapy: Patients who refuse or have contraindications to immunomodulatory therapies 1, 2

Preferred agents: Start with semaglutide or liraglutide given strongest evidence 6, 2

Monitoring: Assess PASI and weight at 12-week intervals; greater weight loss predicts better skin response 1

Safety Profile

GLP-1 agonists combine safely with methotrexate, cyclosporine, and biologics 2. Adverse effects are predominantly:

  • Transient gastrointestinal symptoms (nausea, vomiting, diarrhea)
  • Rare: pancreatitis, gallbladder events 2

Important caveat: Paradoxical psoriasiform eruptions and psoriasis exacerbations have been reported with some agents 6. Monitor for disease flares, particularly in the first 4-8 weeks.

Limitations of Current Evidence

The evidence base has significant constraints:

  • Most studies are small (7-48 patients), short-term (≤6 months), and lack control groups 2
  • Heterogeneous study designs and variable follow-up times 8
  • Confounding effects from concurrent therapies 7
  • Limited data in patients without metabolic comorbidities 7

Despite these limitations, the consistency of benefit across multiple studies, combined with the favorable safety profile and ability to address cardiometabolic comorbidities common in psoriasis patients, supports their clinical use in appropriately selected patients.

Practical Implementation

For severe psoriasis with obesity/diabetes: Initiate GLP-1 agonist (semaglutide or liraglutide) as first-line or add to existing biologic therapy if response is inadequate.

For severe psoriasis without metabolic disease: Prioritize guideline-recommended biologics (IL-17, IL-23, or IL-12/23 inhibitors) as first-line 4. Reserve GLP-1 agonists for patients declining immunosuppression or with contraindications.

Combination approach: GLP-1 agonists can be safely combined with topical corticosteroids, vitamin D analogs, and systemic therapies per established guidelines 3, 2.

References

Related Questions

In a 61-year-old female with psoriasis, type 2 diabetes mellitus, insomnia, and current medications glimepiride, metformin, voglibose, pregabalin, methylcobalamin, escitalopram, and rabeprazole, who presents with left‑shoulder pain with diaphoresis, uncontrolled diarrhea after eating outside food, and generalized weakness, what immediate investigations and medication adjustments are indicated?
In a 42-year-old woman with ankylosing spondylitis and suspected psoriasis, could a glucagon-like peptide-1 (GLP-1) receptor agonist be helpful?
In a 61-year-old female with psoriasis and type 2 diabetes on glimepiride, metformin, voglibose, pregabalin, methylcobalamin, escitalopram and psoriasis therapy, who has stable vitals, random glucose ~150 mg/dL, sleeping disturbance, uncontrolled diarrhea with irregular meals, and generalized weakness and fatigue, how should her medication regimen be optimized?
What could be causing increased bruising and skin pallor in a patient with type 2 diabetes on GLP-1 receptor agonist therapy and a normal Complete Blood Count (CBC) result?
What is the recommended treatment for benign paroxysmal positional vertigo (BPPV)?
Why might my shortness of breath after drinking a protein shake be due to underlying cardiopulmonary disease?
What is the recommended treatment for a coccygeal fracture?
What is the appropriate management for an adult with non‑bloody, non‑febrile acute watery diarrhea presenting to an outpatient gastroenterology office?
How should a patient with Sjögren’s syndrome and elevated inflammatory markers be treated?
A 16-year-old female on fluvoxamine (Luvox) 50 mg twice daily has breakthrough panic attacks and anxiety; how should her treatment be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.